Rift Valley Fever Epidemic in Saudi Arabia: Epidemiological, Clinical, and Laboratory Characteristics

This cohort descriptive study summarizes the epidemiological, clinical, and laboratory characteristics of the Rift Valley fever (RVF) epidemic that occurred in Saudi Arabia from 26 August 2000 through 22 September 2001. A total of 886 cases were reported. Of 834 reported cases for which laboratory r...

Full description

Saved in:
Bibliographic Details
Published inClinical infectious diseases Vol. 37; no. 8; pp. 1084 - 1092
Main Authors Madani, Tariq A., Al-Mazrou, Yagob Y., Al-Jeffri, Mohammad H., Mishkhas, Amin A., Al-Rabeah, Abdullah M., Turkistani, Adel M., Al-Sayed, Mohammad O., Abodahish, Abdullah A., Khan, Ali S., Ksiazek, Thomas G., Shobokshi, Osama
Format Journal Article
LanguageEnglish
Published Chicago, IL The University of Chicago Press 15.10.2003
University of Chicago Press
Subjects
Online AccessGet full text
ISSN1058-4838
1537-6591
1537-6591
DOI10.1086/378747

Cover

Loading…
Abstract This cohort descriptive study summarizes the epidemiological, clinical, and laboratory characteristics of the Rift Valley fever (RVF) epidemic that occurred in Saudi Arabia from 26 August 2000 through 22 September 2001. A total of 886 cases were reported. Of 834 reported cases for which laboratory results were available, 81.9% were laboratory confirmed, of which 51.1% were positive for only RVF immunoglobulin M, 35.7% were positive for only RVF antigen, and 13.2% were positive for both. The mean age (± standard deviation) was 46.9 ± 19.4 years, and the ratio of male to female patients was 4 : 1. Clinical and laboratory features included fever (92.6% of patients), nausea (59.4%), vomiting (52.6%), abdominal pain (38.0%), diarrhea (22.1%), jaundice (18.1%), neurological manifestations (17.1%), hemorrhagic manifestations (7.1%), vision loss or scotomas (1.5%), elevated liver enzyme levels (98%), elevated lactate dehydrogenase level (60.2%), thrombocytopenia (38.4%), leukopenia (39.7%), renal impairment or failure (27.8%), elevated creatine kinase level (27.3%), and severe anemia (15.1%). The mortality rate was 13.9%. Bleeding, neurological manifestations, and jaundice were independently associated with a high mortality rate. Patients with leukopenia had significantly a lower mortality rate than did those with a normal or high leukocyte count (2.3% vs. 27.9%; odds ratio, 0.09; 95% confidence interval, 0.01–0.63).
AbstractList This cohort descriptive study summarizes the epidemiological, clinical, and laboratory characteristics of the Rift Valley fever (RVF) epidemic that occurred in Saudi Arabia from 26 August 2000 through 22 September 2001. A total of 886 cases were reported. Of 834 reported cases for which laboratory results were available, 81.9% were laboratory confirmed, of which 51.1% were positive for only RVF immunoglobulin M, 35.7% were positive for only RVF antigen, and 13.2% were positive for both. The mean age (± standard deviation) was 46.9 ± 19.4 years, and the ratio of male to female patients was 4 : 1. Clinical and laboratory features included fever (92.6% of patients), nausea (59.4%), vomiting (52.6%), abdominal pain (38.0%), diarrhea (22.1%), jaundice (18.1%), neurological manifestations (17.1%), hemorrhagic manifestations (7.1%), vision loss or scotomas (1.5%), elevated liver enzyme levels (98%), elevated lactate dehydrogenase level (60.2%), thrombocytopenia (38.4%), leukopenia (39.7%), renal impairment or failure (27.8%), elevated creatine kinase level (27.3%), and severe anemia (15.1%). The mortality rate was 13.9%. Bleeding, neurological manifestations, and jaundice were independently associated with a high mortality rate. Patients with leukopenia had significantly a lower mortality rate than did those with a normal or high leukocyte count (2.3% vs. 27.9%; odds ratio, 0.09; 95% confidence interval, 0.01–0.63).
This cohort descriptive study summarizes the epidemiological, clinical, and laboratory characteristics of the Rift Valley fever (RVF) epidemic that occurred in Saudi Arabia from 26 August 2000 through 22 September 2001. A total of 886 cases were reported. Of 834 reported cases for which laboratory results were available, 81.9% were laboratory confirmed, of which 51.1% were positive for only RVF immunoglobulin M, 35.7% were positive for only RVF antigen, and 13.2% were positive for both. The mean age ( plus or minus standard deviation) was 46.9 plus or minus 19.4 years, and the ratio of male to female patients was 4:1. Clinical and laboratory features included fever (92.6% of patients), nausea (59.4%), vomiting (52.6%), abdominal pain (38.0%), diarrhea (22.1%), jaundice (18.1%), neurological manifestations (17.1%), hemorrhagic manifestations (7.1%), vision loss or scotomas (1.5%), elevated liver enzyme levels (98%), elevated lactate dehydrogenase level (60.2%), thrombocytopenia (38.4%), leukopenia (39.7%), renal impairment or failure (27.8%), elevated creatine kinase level (27.3%), and severe anemia (15.1%). The mortality rate was 13.9%. Bleeding, neurological manifestations, and jaundice were independently associated with a high mortality rate. Patients with leukopenia had significantly a lower mortality rate than did those with a normal or high leukocyte count (2.3% vs. 27.9%; odds ratio, 0.09; 95% confidence interval, 0.01-0.63).
This cohort descriptive study summarizes the epidemiological, clinical, and laboratory characteristics of the Rift Valley fever (RVF) epidemic that occurred in Saudi Arabia from 26 August 2000 through 22 September 2001. A total of 886 cases were reported. Of 834 reported cases for which laboratory results were available, 81.9% were laboratory confirmed, of which 51.1% were positive for only RVF immunoglobulin M, 35.7% were positive for only RVF antigen, and 13.2% were positive for both. The mean age (+/- standard deviation) was 46.9+/-19.4 years, and the ratio of male to female patients was 4:1. Clinical and laboratory features included fever (92.6% of patients), nausea (59.4%), vomiting (52.6%), abdominal pain (38.0%), diarrhea (22.1%), jaundice (18.1%), neurological manifestations (17.1%), hemorrhagic manifestations (7.1%), vision loss or scotomas (1.5%), elevated liver enzyme levels (98%), elevated lactate dehydrogenase level (60.2%), thrombocytopenia (38.4%), leukopenia (39.7%), renal impairment or failure (27.8%), elevated creatine kinase level (27.3%), and severe anemia (15.1%). The mortality rate was 13.9%. Bleeding, neurological manifestations, and jaundice were independently associated with a high mortality rate. Patients with leukopenia had significantly a lower mortality rate than did those with a normal or high leukocyte count (2.3% vs. 27.9%; odds ratio, 0.09; 95% confidence interval, 0.01-0.63).This cohort descriptive study summarizes the epidemiological, clinical, and laboratory characteristics of the Rift Valley fever (RVF) epidemic that occurred in Saudi Arabia from 26 August 2000 through 22 September 2001. A total of 886 cases were reported. Of 834 reported cases for which laboratory results were available, 81.9% were laboratory confirmed, of which 51.1% were positive for only RVF immunoglobulin M, 35.7% were positive for only RVF antigen, and 13.2% were positive for both. The mean age (+/- standard deviation) was 46.9+/-19.4 years, and the ratio of male to female patients was 4:1. Clinical and laboratory features included fever (92.6% of patients), nausea (59.4%), vomiting (52.6%), abdominal pain (38.0%), diarrhea (22.1%), jaundice (18.1%), neurological manifestations (17.1%), hemorrhagic manifestations (7.1%), vision loss or scotomas (1.5%), elevated liver enzyme levels (98%), elevated lactate dehydrogenase level (60.2%), thrombocytopenia (38.4%), leukopenia (39.7%), renal impairment or failure (27.8%), elevated creatine kinase level (27.3%), and severe anemia (15.1%). The mortality rate was 13.9%. Bleeding, neurological manifestations, and jaundice were independently associated with a high mortality rate. Patients with leukopenia had significantly a lower mortality rate than did those with a normal or high leukocyte count (2.3% vs. 27.9%; odds ratio, 0.09; 95% confidence interval, 0.01-0.63).
This cohort descriptive study summarizes the epidemiological, clinical, and laboratory characteristics of the Rift Valley fever (RVF) epidemic that occurred in Saudi Arabia from 26 August 2000 through 22 September 2001. A total of 886 cases were reported. Of 834 reported cases for which laboratory results were available, 81.9% were laboratory confirmed, of which 51.1% were positive for only RVF immunoglobulin M, 35.7% were positive for only RVF antigen, and 13.2% were positive for both. The mean age (+/- standard deviation) was 46.9+/-19.4 years, and the ratio of male to female patients was 4:1. Clinical and laboratory features included fever (92.6% of patients), nausea (59.4%), vomiting (52.6%), abdominal pain (38.0%), diarrhea (22.1%), jaundice (18.1%), neurological manifestations (17.1%), hemorrhagic manifestations (7.1%), vision loss or scotomas (1.5%), elevated liver enzyme levels (98%), elevated lactate dehydrogenase level (60.2%), thrombocytopenia (38.4%), leukopenia (39.7%), renal impairment or failure (27.8%), elevated creatine kinase level (27.3%), and severe anemia (15.1%). The mortality rate was 13.9%. Bleeding, neurological manifestations, and jaundice were independently associated with a high mortality rate. Patients with leukopenia had significantly a lower mortality rate than did those with a normal or high leukocyte count (2.3% vs. 27.9%; odds ratio, 0.09; 95% confidence interval, 0.01-0.63).
Author Al-Rabeah, Abdullah M.
Turkistani, Adel M.
Al-Sayed, Mohammad O.
Al-Mazrou, Yagob Y.
Mishkhas, Amin A.
Abodahish, Abdullah A.
Khan, Ali S.
Shobokshi, Osama
Ksiazek, Thomas G.
Madani, Tariq A.
Al-Jeffri, Mohammad H.
Author_xml – sequence: 1
  givenname: Tariq A.
  surname: Madani
  fullname: Madani, Tariq A.
  email: taamadani@yahoo.com
  organization: Ministry of Health, Riyadh, Saudi Arabia
– sequence: 2
  givenname: Yagob Y.
  surname: Al-Mazrou
  fullname: Al-Mazrou, Yagob Y.
  organization: Ministry of Health, Riyadh, Saudi Arabia
– sequence: 3
  givenname: Mohammad H.
  surname: Al-Jeffri
  fullname: Al-Jeffri, Mohammad H.
  organization: Ministry of Health, Riyadh, Saudi Arabia
– sequence: 4
  givenname: Amin A.
  surname: Mishkhas
  fullname: Mishkhas, Amin A.
  organization: Ministry of Health, Riyadh, Saudi Arabia
– sequence: 5
  givenname: Abdullah M.
  surname: Al-Rabeah
  fullname: Al-Rabeah, Abdullah M.
  organization: Ministry of Health, Riyadh, Saudi Arabia
– sequence: 6
  givenname: Adel M.
  surname: Turkistani
  fullname: Turkistani, Adel M.
  organization: Ministry of Health, Riyadh, Saudi Arabia
– sequence: 7
  givenname: Mohammad O.
  surname: Al-Sayed
  fullname: Al-Sayed, Mohammad O.
  organization: Ministry of Health, Riyadh, Saudi Arabia
– sequence: 8
  givenname: Abdullah A.
  surname: Abodahish
  fullname: Abodahish, Abdullah A.
  organization: Ministry of Health, Riyadh, Saudi Arabia
– sequence: 9
  givenname: Ali S.
  surname: Khan
  fullname: Khan, Ali S.
  organization: Special Pathogens Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
– sequence: 10
  givenname: Thomas G.
  surname: Ksiazek
  fullname: Ksiazek, Thomas G.
  organization: Special Pathogens Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
– sequence: 11
  givenname: Osama
  surname: Shobokshi
  fullname: Shobokshi, Osama
  organization: Ministry of Health, Riyadh, Saudi Arabia
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15235401$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/14523773$$D View this record in MEDLINE/PubMed
BookMark eNqF0ltrFDEUB_AgFXtRP4HI-KBPHU0mtxnfytB2SxcEL7X0JZzJJJo6O1mTjLjf3shsu6CITzlwfjmB888h2hv9aBB6SvBrgmvxhspaMvkAHRBOZSl4Q_ZyjXldsprW--gwxluMCakxf4T2CeMVlZIeIPPe2VRcwTCYTXFmfphQnK5db1ZOF24sPsDUu-IkQOfg7V3HD_6L0zAcF-3gxrmCsS-W0PkAyYdN0X6FADqZ4GJyOj5GDy0M0TzZnkfo09npx3ZRLt-dX7Qny1IzTlNpSVdpI5gQnGBrq8qSHjSnvGsAWwa1lKaTFXDJLBUM14TX0BFmuBWME0mP0Kt57jr475OJSa1c1GYYYDR-ikrmmwRL_F9IGtJQIpoMn2_h1K1Mr9bBrSBs1N0GM3i5BRDzJmyAUbu4c5lxhsnuRR18jMHYHcHqd4RqjjDD4z-gdgmS82MK4Ia_-YuZ-2n975HPZnMbczr3iuWvIaoqt8u5ncMyP-_bEL4pIankanF9oz5ftzfnV4tGXdJf1yW8bw
CODEN CIDIEL
CitedBy_id crossref_primary_10_1371_journal_pntd_0011677
crossref_primary_10_2987_10_6070_1
crossref_primary_10_3402_iee_v5_28024
crossref_primary_10_1371_journal_pntd_0008143
crossref_primary_10_3923_ajava_2015_781_788
crossref_primary_10_1002_vms3_135
crossref_primary_10_1371_journal_pone_0305521
crossref_primary_10_1016_j_celrep_2018_12_001
crossref_primary_10_1080_13550280591002450
crossref_primary_10_3390_pathogens13100856
crossref_primary_10_20473_javest_V5_I1_2024_78_82
crossref_primary_10_1016_j_virol_2011_08_024
crossref_primary_10_1186_s12985_018_1071_y
crossref_primary_10_1016_j_respe_2015_03_124
crossref_primary_10_1371_journal_pone_0251263
crossref_primary_10_1371_journal_pntd_0007979
crossref_primary_10_1128_JVI_01662_17
crossref_primary_10_14202_vetworld_2022_1990_1995
crossref_primary_10_1371_journal_pntd_0010339
crossref_primary_10_3390_vetsci7030103
crossref_primary_10_1128_mSphere_00798_20
crossref_primary_10_1371_journal_ppat_1003922
crossref_primary_10_2987_14_6441R_1
crossref_primary_10_1080_1040841X_2018_1446901
crossref_primary_10_3201_eid2811_220364
crossref_primary_10_3390_ijms232012492
crossref_primary_10_1128_JVI_01506_21
crossref_primary_10_3390_v11010035
crossref_primary_10_1007_s11030_023_10702_x
crossref_primary_10_1126_sciadv_adh2264
crossref_primary_10_1371_journal_pntd_0002156
crossref_primary_10_1016_j_medmal_2010_12_007
crossref_primary_10_1128_jvi_00415_23
crossref_primary_10_1128_JVI_02095_06
crossref_primary_10_3390_tropicalmed5020089
crossref_primary_10_1089_vbz_2010_0084
crossref_primary_10_1186_s13620_016_0065_6
crossref_primary_10_1016_j_antiviral_2014_03_008
crossref_primary_10_1371_journal_ppat_1007833
crossref_primary_10_1016_j_copbio_2008_10_009
crossref_primary_10_1093_cid_cir732
crossref_primary_10_2903_j_efsa_2020_6292
crossref_primary_10_1016_j_vaccine_2013_09_029
crossref_primary_10_1016_j_vaccine_2010_04_048
crossref_primary_10_1371_journal_pone_0065786
crossref_primary_10_1080_21505594_2024_2384563
crossref_primary_10_3390_v15122369
crossref_primary_10_1038_s41541_017_0021_9
crossref_primary_10_1155_2018_4956378
crossref_primary_10_1371_journal_pntd_0006627
crossref_primary_10_3390_pathogens13020159
crossref_primary_10_1016_j_aspen_2017_12_001
crossref_primary_10_1016_j_vaccine_2017_04_085
crossref_primary_10_1016_j_medmal_2010_12_010
crossref_primary_10_4269_ajtmh_2010_09_0293
crossref_primary_10_1016_j_jcv_2012_07_004
crossref_primary_10_1186_s12985_024_02602_9
crossref_primary_10_1016_j_onehlt_2023_100583
crossref_primary_10_1111_tbed_12267
crossref_primary_10_1371_journal_pntd_0000763
crossref_primary_10_1371_journal_pntd_0006175
crossref_primary_10_1093_jmedent_45_1_102
crossref_primary_10_1007_s40588_018_0110_1
crossref_primary_10_3390_microorganisms10010092
crossref_primary_10_1371_journal_pntd_0005082
crossref_primary_10_1186_1471_2334_6_135
crossref_primary_10_1186_s13071_016_1383_y
crossref_primary_10_1016_j_virol_2015_12_003
crossref_primary_10_1016_S2222_1808_15_60993_8
crossref_primary_10_3390_pathogens13070582
crossref_primary_10_1371_journal_pone_0066626
crossref_primary_10_1186_s12936_023_04467_9
crossref_primary_10_1128_JVI_02341_13
crossref_primary_10_1016_j_idc_2019_08_003
crossref_primary_10_1089_vbz_2014_1686
crossref_primary_10_4269_ajtmh_2010_09_0288
crossref_primary_10_1371_journal_pntd_0004314
crossref_primary_10_1007_s12250_016_3876_4
crossref_primary_10_1016_j_intimp_2018_09_002
crossref_primary_10_1093_jme_tjad060
crossref_primary_10_3390_v10040191
crossref_primary_10_1186_s13071_019_3417_8
crossref_primary_10_1371_journal_pntd_0009273
crossref_primary_10_1016_j_jviromet_2019_113701
crossref_primary_10_1016_j_indcrop_2025_120744
crossref_primary_10_1177_0309133313478315
crossref_primary_10_1016_j_cll_2004_05_001
crossref_primary_10_1016_S1155_1976_12_59748_2
crossref_primary_10_1017_dmp_2025_27
crossref_primary_10_1371_journal_pntd_0001557
crossref_primary_10_1016_S2222_1808_15_60944_6
crossref_primary_10_1128_JVI_02055_15
crossref_primary_10_1371_journal_pntd_0007898
crossref_primary_10_1093_jmedent_47_5_884
crossref_primary_10_1002_vms3_848
crossref_primary_10_1016_S0213_005X_05_75042_4
crossref_primary_10_1128_JVI_01519_08
crossref_primary_10_3389_fmicb_2020_590732
crossref_primary_10_1016_j_peptides_2021_170570
crossref_primary_10_1016_j_virol_2009_11_001
crossref_primary_10_1111_zph_12153
crossref_primary_10_1002_vms3_1238
crossref_primary_10_1016_j_puhe_2015_07_034
crossref_primary_10_1186_1743_422X_6_125
crossref_primary_10_3390_v8050145
crossref_primary_10_1016_j_vaccine_2012_03_027
crossref_primary_10_1128_JVI_01394_19
crossref_primary_10_1007_s11250_017_1359_8
crossref_primary_10_11603_1681_2727_2019_4_10964
crossref_primary_10_1016_j_virol_2012_05_012
crossref_primary_10_4102_ojvr_v86i1_1683
crossref_primary_10_1016_j_bbamem_2014_04_015
crossref_primary_10_1128_JCM_00936_07
crossref_primary_10_1021_acsomega_1c06513
crossref_primary_10_1371_journal_pntd_0005226
crossref_primary_10_1371_journal_pntd_0003045
crossref_primary_10_1371_journal_pone_0116722
crossref_primary_10_1371_journal_pntd_0001423
crossref_primary_10_1371_journal_ppat_1010649
crossref_primary_10_4269_ajtmh_2010_09_0463
crossref_primary_10_7759_cureus_48284
crossref_primary_10_3390_v11020139
crossref_primary_10_1371_journal_pntd_0010482
crossref_primary_10_1016_j_vaccine_2017_10_036
crossref_primary_10_1186_s12917_020_02455_8
crossref_primary_10_1089_vbz_2010_0040
crossref_primary_10_1111_tbed_12903
crossref_primary_10_2987_5645_1
crossref_primary_10_3390_v14112470
crossref_primary_10_1073_pnas_1112149108
crossref_primary_10_3389_fmicb_2015_00787
crossref_primary_10_1016_j_antiviral_2014_10_001
crossref_primary_10_3390_v15020306
crossref_primary_10_3389_fmicb_2015_01509
crossref_primary_10_1016_j_cell_2024_09_008
crossref_primary_10_3201_eid1606_091266
crossref_primary_10_1128_JVI_02501_07
crossref_primary_10_1016_j_vaccine_2011_02_037
crossref_primary_10_1086_383576
crossref_primary_10_1016_j_cell_2021_09_001
crossref_primary_10_3390_v6031410
crossref_primary_10_1007_s00436_025_08457_5
crossref_primary_10_1371_journal_pone_0217497
crossref_primary_10_1371_journal_pntd_0010233
crossref_primary_10_2217_fvl_2017_0060
crossref_primary_10_1111_2049_632X_12157
crossref_primary_10_3390_pathogens10060708
crossref_primary_10_1099_jgv_0_001522
crossref_primary_10_1038_s41541_019_0138_0
crossref_primary_10_1128_mSphere_00090_17
crossref_primary_10_4236_ojpm_2013_31004
crossref_primary_10_1371_journal_pntd_0001529
crossref_primary_10_1186_s12985_016_0509_3
crossref_primary_10_1603_ME13049
crossref_primary_10_1007_s12010_017_2592_3
crossref_primary_10_3390_v8070194
crossref_primary_10_1186_s41182_019_0178_1
crossref_primary_10_1016_j_onehlt_2022_100470
crossref_primary_10_1111_tbed_14415
crossref_primary_10_1007_s11250_023_03765_3
crossref_primary_10_1371_journal_pntd_0006412
crossref_primary_10_2222_jsv_70_3
crossref_primary_10_1186_s12936_016_1581_2
crossref_primary_10_1177_0300985809354350
crossref_primary_10_1371_journal_pntd_0003095
crossref_primary_10_15585_mmwr_mm6543a5
crossref_primary_10_3390_v2030731
crossref_primary_10_1093_jme_tjv093
crossref_primary_10_1016_j_ophtha_2004_09_018
crossref_primary_10_1186_s12985_024_02377_z
crossref_primary_10_4102_ojvr_v79i2_466
crossref_primary_10_3390_v15112140
crossref_primary_10_1099_jgv_0_000765
crossref_primary_10_1371_journal_pone_0309288
crossref_primary_10_3390_v12030259
crossref_primary_10_3390_v13040709
crossref_primary_10_1186_1743_422X_7_97
crossref_primary_10_1673_031_011_17601
crossref_primary_10_4102_jsava_v88_1379
crossref_primary_10_1016_S1245_1789_08_70235_X
crossref_primary_10_1038_s41598_024_53774_x
crossref_primary_10_1371_journal_pntd_0003536
crossref_primary_10_3390_v11100919
crossref_primary_10_2987_08_5791_1
crossref_primary_10_1016_j_vetmic_2014_04_007
crossref_primary_10_1097_IPC_0b013e31814b1b36
crossref_primary_10_1016_j_coviro_2012_02_017
crossref_primary_10_1016_j_epidem_2020_100409
crossref_primary_10_1093_ofid_ofw200
crossref_primary_10_2987_11_6176_1
crossref_primary_10_1016_j_ijid_2009_03_029
crossref_primary_10_1089_vbz_2019_2532
crossref_primary_10_1093_infdis_jiaf060
crossref_primary_10_2139_ssrn_1027752
crossref_primary_10_1016_j_vaccine_2017_04_024
crossref_primary_10_1128_JCM_01412_08
crossref_primary_10_1371_journal_pntd_0006474
crossref_primary_10_1038_srep05824
crossref_primary_10_1007_s11481_010_9234_7
crossref_primary_10_1038_s41598_023_29023_y
crossref_primary_10_1017_S0950268807009806
crossref_primary_10_3389_fimmu_2022_1084230
crossref_primary_10_1186_s12985_017_0811_8
crossref_primary_10_1172_jci_insight_180151
crossref_primary_10_3201_eid1712_110658
crossref_primary_10_1186_1746_6148_10_92
crossref_primary_10_1128_JCM_01905_08
crossref_primary_10_1016_j_antiviral_2018_05_009
crossref_primary_10_1016_j_antiviral_2009_10_008
crossref_primary_10_1371_journal_pntd_0001229
crossref_primary_10_2987_8756_971X_2007_23_226_POAAIL_2_0_CO_2
crossref_primary_10_1111_tbed_12331
crossref_primary_10_1093_infdis_jir249
crossref_primary_10_3389_fmicb_2023_1114226
crossref_primary_10_1371_journal_pntd_0002430
crossref_primary_10_1016_j_jiph_2012_11_011
crossref_primary_10_1038_emi_2013_81
crossref_primary_10_1016_j_jviromet_2011_12_013
crossref_primary_10_1371_journal_pntd_0002670
crossref_primary_10_1146_annurev_virology_091919_065806
crossref_primary_10_1371_journal_pntd_0002435
crossref_primary_10_3390_v13061079
crossref_primary_10_1136_bcr_2016_216054
crossref_primary_10_1016_j_virol_2007_01_046
crossref_primary_10_1371_journal_pntd_0009852
crossref_primary_10_1016_j_jim_2018_06_006
crossref_primary_10_1371_journal_pntd_0006460
crossref_primary_10_1007_s13546_011_0262_y
crossref_primary_10_1080_24725579_2024_2370243
crossref_primary_10_1089_vbz_2010_0245
crossref_primary_10_1177_0300985820954549
crossref_primary_10_1111_tra_12393
crossref_primary_10_1371_journal_ppat_1002661
crossref_primary_10_1016_j_vaccine_2015_08_020
crossref_primary_10_1371_journal_pntd_0004840
crossref_primary_10_3201_eid1902_120941
crossref_primary_10_1016_j_tmaid_2008_09_008
crossref_primary_10_1371_journal_pone_0077461
crossref_primary_10_4102_ojvr_v87i1_1877
crossref_primary_10_1016_j_vaccine_2011_04_043
crossref_primary_10_1089_vbz_2019_2554
crossref_primary_10_1128_JVI_01270_18
crossref_primary_10_1016_j_actatropica_2012_12_013
crossref_primary_10_1088_1758_5090_ad4c0b
crossref_primary_10_1016_j_virol_2011_09_023
crossref_primary_10_1186_s12941_020_0346_5
crossref_primary_10_1038_emi_2014_71
crossref_primary_10_3923_javaa_2010_258_265
crossref_primary_10_1038_s41598_020_65683_w
crossref_primary_10_3201_eid1408_080082
crossref_primary_10_1089_vbz_2015_1774
crossref_primary_10_1016_j_vaccine_2015_12_030
crossref_primary_10_1128_CVI_00114_15
crossref_primary_10_2217_fvl_14_62
crossref_primary_10_1093_ilar_ilx023
crossref_primary_10_1590_1678_4685_gmb_2019_0240
crossref_primary_10_1016_j_antiviral_2017_04_011
crossref_primary_10_1099_jgv_0_001296
crossref_primary_10_1099_jgv_0_001970
crossref_primary_10_1016_j_jviromet_2019_04_011
crossref_primary_10_3390_vaccines10111794
crossref_primary_10_18357_anthropologica66120242646
crossref_primary_10_1007_s00705_021_05083_1
crossref_primary_10_3201_eid1902_120834
crossref_primary_10_1371_journal_pntd_0005002
crossref_primary_10_1016_j_cll_2017_01_004
crossref_primary_10_1016_j_actatropica_2012_04_007
crossref_primary_10_1016_j_smallrumres_2011_03_011
crossref_primary_10_1080_21645515_2019_1627820
crossref_primary_10_1007_s11250_019_01978_z
crossref_primary_10_1016_j_microb_2023_100016
crossref_primary_10_24880_maeuvfd_260789
crossref_primary_10_1080_13550280591002496
crossref_primary_10_1371_journal_pone_0259466
crossref_primary_10_1371_journal_pntd_0002244
crossref_primary_10_1016_j_ijid_2020_07_043
crossref_primary_10_1186_s12917_017_0993_8
crossref_primary_10_1371_journal_pntd_0005756
crossref_primary_10_1089_vbz_2019_2458
crossref_primary_10_1186_1471_2334_13_136
crossref_primary_10_4161_hv_20202
crossref_primary_10_1128_jvi_00853_23
crossref_primary_10_1371_journal_pntd_0007258
crossref_primary_10_1177_20503121241229847
crossref_primary_10_3389_fvets_2024_1489815
crossref_primary_10_1371_journal_pone_0209929
crossref_primary_10_1146_annurev_virology_093022_011544
crossref_primary_10_1038_srep20617
crossref_primary_10_3389_fimmu_2022_907675
crossref_primary_10_1371_journal_pntd_0001265
crossref_primary_10_1038_s41541_020_00218_y
crossref_primary_10_1371_journal_pntd_0002237
crossref_primary_10_1016_j_prevetmed_2023_106071
crossref_primary_10_1371_journal_pntd_0002356
crossref_primary_10_1073_pnas_1607948114
crossref_primary_10_1136_bmjgh_2020_002694
crossref_primary_10_1007_s13149_011_0165_1
crossref_primary_10_3390_v16071148
crossref_primary_10_1016_j_antiviral_2009_08_002
crossref_primary_10_1371_journal_pntd_0000725
crossref_primary_10_1371_journal_pone_0128215
crossref_primary_10_4102_ojvr_v88i1_1877
crossref_primary_10_4269_ajtmh_2010_83s2a01
crossref_primary_10_1371_journal_pntd_0005731
crossref_primary_10_1039_C7CP02695A
crossref_primary_10_3389_fneur_2021_634827
crossref_primary_10_1017_S0950268810001020
crossref_primary_10_1371_journal_ppat_1010231
crossref_primary_10_1093_jhered_esv087
crossref_primary_10_4001_003_022_0402
crossref_primary_10_1016_j_virusres_2012_07_019
crossref_primary_10_1128_JVI_06190_11
crossref_primary_10_1016_j_sjbs_2016_07_003
crossref_primary_10_4254_wjh_v11_i1_37
crossref_primary_10_1016_j_idc_2012_02_003
crossref_primary_10_1186_s12879_015_1099_1
crossref_primary_10_47485_2767_5416_1084
crossref_primary_10_2460_ajvr_71_5_522
crossref_primary_10_1016_j_virol_2018_10_021
crossref_primary_10_1051_vetres_2010033
crossref_primary_10_1038_s41598_023_42596_y
crossref_primary_10_3389_fitd_2023_1240420
crossref_primary_10_1186_1743_422X_9_139
crossref_primary_10_1016_j_virol_2010_08_016
crossref_primary_10_14202_IJOH_2021_237_245
crossref_primary_10_1128_JVI_06046_11
crossref_primary_10_1016_j_coviro_2017_10_007
crossref_primary_10_1038_gene_2014_79
crossref_primary_10_1128_AAC_03595_14
Cites_doi 10.1016/0140-6736(93)92128-G
10.1016/S0923-2516(89)80081-0
10.1086/514321
10.3201/eid0812.020195
10.3201/eid0802.010023
10.1002/path.1700340418
10.1016/0035-9203(79)90004-X
10.1016/0035-9203(79)90006-3
10.1016/S0923-2516(89)80090-1
ContentType Journal Article
Copyright Copyright 2003 The Infectious Diseases Society of America
2003 by the Infectious Diseases Society of America 2003
2004 INIST-CNRS
Copyright_xml – notice: Copyright 2003 The Infectious Diseases Society of America
– notice: 2003 by the Infectious Diseases Society of America 2003
– notice: 2004 INIST-CNRS
DBID BSCLL
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7U9
H94
7X8
DOI 10.1086/378747
DatabaseName Istex
CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
Virology and AIDS Abstracts
MEDLINE - Academic
DatabaseTitleList
AIDS and Cancer Research Abstracts

MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1537-6591
EndPage 1092
ExternalDocumentID 14523773
15235401
10_1086_378747
10.1086/378747
4483622
ark_67375_HXZ_WXCZGVH9_K
Genre Journal Article
GeographicLocations Saudi Arabia
Asia
Yemen
GeographicLocations_xml – name: Saudi Arabia
– name: Yemen
GroupedDBID ---
..I
.2P
.GJ
.I3
.ZR
08P
0R~
1TH
29B
2AX
2WC
36B
3O-
4.4
48X
53G
5GY
5RE
5VS
5WD
6J9
AABZA
AACGO
AACZT
AAJKP
AAJQQ
AAMVS
AANCE
AAOGV
AAPQZ
AAPXW
AAQQT
AARHZ
AAUAY
AAUQX
AAVAP
ABBHK
ABDFA
ABEJV
ABEUO
ABGNP
ABIXL
ABJNI
ABLJU
ABNGD
ABNHQ
ABOCM
ABPLY
ABPQP
ABPTD
ABQLI
ABQNK
ABTLG
ABVGC
ABWST
ABXSQ
ABXVV
ACGFO
ACGFS
ACHIC
ACPRK
ACUFI
ACUKT
ACUTO
ACYHN
ADBBV
ADGZP
ADHKW
ADHZD
ADIPN
ADNBA
ADQBN
ADQXQ
ADRTK
ADULT
ADVEK
ADYVW
ADZXQ
AEGPL
AEGXH
AEJOX
AEKSI
AEMDU
AEMQT
AENEX
AENZO
AEPUE
AETBJ
AEUPB
AEWNT
AEXZC
AFFNX
AFFZL
AFIYH
AFOFC
AFRAH
AFXAL
AGINJ
AGORE
AGQPQ
AGQXC
AGSYK
AGUTN
AHMBA
AHMMS
AHXPO
AI.
AIAGR
AJBYB
AJEEA
AJNCP
ALMA_UNASSIGNED_HOLDINGS
ALUQC
ALXQX
APIBT
APWMN
AQKUS
AQVQM
ASPBG
ATGXG
AVWKF
AXUDD
AZFZN
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BSCLL
BTRTY
BVRKM
C1A
C45
CDBKE
CS3
CZ4
DAKXR
DCCCD
DIK
DILTD
DU5
D~K
E3Z
EBS
EE~
EJD
EMOBN
ENERS
F5P
F9B
FECEO
FEDTE
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
H5~
HAR
HQ3
HTVGU
HVGLF
HW0
HZ~
IOX
IPSME
J21
J5H
JAAYA
JBMMH
JENOY
JHFFW
JKQEH
JLS
JLXEF
JPM
JSG
JST
JXSIZ
KAQDR
KBUDW
KOP
KSI
KSN
L7B
MHKGH
MJL
ML0
N4W
N9A
NGC
NOMLY
NOYVH
NU-
NVLIB
O0~
O9-
OAUYM
OAWHX
OCZFY
ODMLO
ODZKP
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
P2P
P6G
PAFKI
PB-
PEELM
PQQKQ
Q1.
Q5Y
QBD
RD5
ROX
ROZ
RUSNO
RW1
RXO
SA0
SJN
TCURE
TEORI
TJX
TMA
TR2
VH1
W8F
X7H
YAYTL
YKOAZ
YXANX
ZGI
~91
~S-
AAYOK
AASNB
ADACV
ADJQC
ADRIX
AFXEN
DOOOF
ESX
JSODD
M49
AAYXX
CITATION
1KJ
70D
AAPGJ
AAPNW
AAWDT
ABKDP
ABNKS
ABSMQ
ABZBJ
ACFRR
ACPQN
ACUTJ
ACVCV
ACZBC
ADEYI
ADMTO
ADOCK
AEKPW
AFFQV
AFSHK
AFYAG
AGKEF
AGKRT
AGMDO
AHGBF
AIJHB
AJDVS
APJGH
AQDSO
AVNTJ
BZKNY
EIHJH
H13
IQODW
MBLQV
OBFPC
O~Y
Y6R
CGR
CUY
CVF
ECM
EIF
NPM
7U9
H94
7X8
ID FETCH-LOGICAL-c453t-f1b2ce6466510ff22f1dac535b9a0f4a877eb72a574f36408158ab14e5f645173
ISSN 1058-4838
1537-6591
IngestDate Fri Sep 05 04:28:58 EDT 2025
Tue Aug 05 09:42:27 EDT 2025
Wed Feb 19 01:51:05 EST 2025
Mon Jul 21 09:13:39 EDT 2025
Thu Apr 24 23:11:06 EDT 2025
Tue Jul 01 04:28:39 EDT 2025
Wed Sep 11 04:49:12 EDT 2024
Thu Jun 19 15:26:07 EDT 2025
Tue Aug 05 16:49:09 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 8
Keywords Prognosis
Male
Hemopathy
Epidemiology
Visual field disease
Vomiting
Cohort study
Arbovirus disease
Intestinal disease
Female
Carbohydrate
Age
Kidney disease
Epidemic
Rift valley fever
Human
Immunoglobulins
Urinary system disease
Critically ill
Characteristic
Diarrhea
Nausea
Standards
Infection
Antigen
Case study
Symptomatology
Eye disease
Metabolic disorder
Platelet
Viral disease
Digestive diseases
Lactic acid
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c453t-f1b2ce6466510ff22f1dac535b9a0f4a877eb72a574f36408158ab14e5f645173
Notes ark:/67375/HXZ-WXCZGVH9-K
istex:65C0FF02C3A9B103128EA4822B7B2D0A6792673A
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
OpenAccessLink https://academic.oup.com/cid/article-pdf/37/8/1084/5910138/37-8-1084.pdf
PMID 14523773
PQID 19193169
PQPubID 23462
PageCount 9
ParticipantIDs proquest_miscellaneous_75741070
proquest_miscellaneous_19193169
pubmed_primary_14523773
pascalfrancis_primary_15235401
crossref_primary_10_1086_378747
crossref_citationtrail_10_1086_378747
oup_primary_10_1086_378747
jstor_primary_4483622
istex_primary_ark_67375_HXZ_WXCZGVH9_K
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2003-10-15
PublicationDateYYYYMMDD 2003-10-15
PublicationDate_xml – month: 10
  year: 2003
  text: 2003-10-15
  day: 15
PublicationDecade 2000
PublicationPlace Chicago, IL
PublicationPlace_xml – name: Chicago, IL
– name: United States
PublicationTitle Clinical infectious diseases
PublicationTitleAbbrev Clinical Infectious Diseases
PublicationTitleAlternate Clinical Infectious Diseases
PublicationYear 2003
Publisher The University of Chicago Press
University of Chicago Press
Publisher_xml – name: The University of Chicago Press
– name: University of Chicago Press
References Anderson (12_5335291) 1989; 140
Woods (17_16961167) 2002; 8
Zaki (13_15800967) 1995; 146
(10_26479589) 1999; 179
van Velden (15_4336408) 1977; 51
(9_5982062) 1998; 47
Shoemaker (11_17384930) 2002; 8
(2_23806421) 1931; 34
El-Gebaly (5_7886887) 1978; 53
Meegan (6_8068707) 1979; 73
(14_43933339) 1979; 73
Arthur (8_14505517) 1993; 342
Digoutte (7_5228285) 1989; 140
15156493 - Clin Infect Dis. 2004 May 15;38(10):1503
References_xml – volume: 342
  start-page: 1149
  issn: 0140-6736
  issue: 8880
  year: 1993
  ident: 8_14505517
  publication-title: Lancet
  doi: 10.1016/0140-6736(93)92128-G
– volume: 140
  start-page: 27
  issn: 0923-2516
  issue: 1
  year: 1989
  ident: 7_5228285
  publication-title: Research in virology
  doi: 10.1016/S0923-2516(89)80081-0
– volume: 179
  start-page: 177
  issn: 0022-1899
  year: 1999
  ident: 10_26479589
  publication-title: Journal of Infectious Diseases
  doi: 10.1086/514321
– volume: 8
  start-page: 1415
  issn: 1080-6040
  issue: 12
  year: 2002
  ident: 11_17384930
  publication-title: Emerging infectious diseases
  doi: 10.3201/eid0812.020195
– volume: 8
  start-page: 138
  issn: 1080-6040
  issue: 2
  year: 2002
  ident: 17_16961167
  publication-title: Emerging infectious diseases
  doi: 10.3201/eid0802.010023
– volume: 47
  start-page: 261
  issn: 0149-2195
  issue: 13
  year: 1998
  ident: 9_5982062
  publication-title: MMWR. Morbidity and mortality weekly report
– volume: 34
  start-page: 545
  issn: 0368-3494
  year: 1931
  ident: 2_23806421
  publication-title: The Journal of pathology and bacteriology
  doi: 10.1002/path.1700340418
– volume: 51
  start-page: 867
  issn: 0038-2469
  issue: 24
  year: 1977
  ident: 15_4336408
  publication-title: South African medical journal. Suid-Afrikaanse tydskrif vir geneeskunde
– volume: 73
  start-page: 618
  issn: 0035-9203
  issue: 6
  year: 1979
  ident: 6_8068707
  publication-title: Transactions of The Royal Society of Tropical Medicine and Hygiene
  doi: 10.1016/0035-9203(79)90004-X
– volume: 146
  start-page: 552
  issn: 0002-9440
  issue: 3
  year: 1995
  ident: 13_15800967
  publication-title: American Journal Of Pathology
– volume: 53
  start-page: 137
  issn: 0013-2446
  issue: 3-4
  year: 1978
  ident: 5_7886887
  publication-title: The Journal of the Egyptian Public Health Association
– volume: 73
  start-page: 630
  issn: 0035-9203
  issue: 6
  year: 1979
  ident: 14_43933339
  publication-title: Transactions of The Royal Society of Tropical Medicine and Hygiene
  doi: 10.1016/0035-9203(79)90006-3
– volume: 140
  start-page: 129
  issn: 0923-2516
  issue: 2
  year: 1989
  ident: 12_5335291
  publication-title: Research in virology
  doi: 10.1016/S0923-2516(89)80090-1
– reference: 15156493 - Clin Infect Dis. 2004 May 15;38(10):1503
SSID ssj0011805
Score 2.3220189
Snippet This cohort descriptive study summarizes the epidemiological, clinical, and laboratory characteristics of the Rift Valley fever (RVF) epidemic that occurred in...
SourceID proquest
pubmed
pascalfrancis
crossref
oup
jstor
istex
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1084
SubjectTerms Adolescent
Adult
Aged
Aged, 80 and over
Antigens
Arboviroses
Biological and medical sciences
Child
Disease Outbreaks
Diseases of visual field, optic nerve, optic chiasma and optic tracts
Enzymes
Epidemics
Epidemiology
Female
Fever
Fever - etiology
Geographic regions
Human viral diseases
Humans
Infections
Infectious diseases
Major Articles
Male
Medical sciences
Middle Aged
Miscellaneous
Mortality
Nausea - etiology
Ophthalmology
Rift Valley Fever - epidemiology
Rift Valley Fever - physiopathology
Rift Valley fever virus
Rift valleys
Saudi Arabia - epidemiology
Tropical viral diseases
Viral diseases
Viruses
Vomiting - etiology
Yemen - epidemiology
Title Rift Valley Fever Epidemic in Saudi Arabia: Epidemiological, Clinical, and Laboratory Characteristics
URI https://api.istex.fr/ark:/67375/HXZ-WXCZGVH9-K/fulltext.pdf
https://www.jstor.org/stable/4483622
https://www.ncbi.nlm.nih.gov/pubmed/14523773
https://www.proquest.com/docview/19193169
https://www.proquest.com/docview/75741070
Volume 37
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKJiEkhLgM6IDhB-AlSxUntpPwVpWNwggP0I1uL5GTOqza2o5eEOxv8Qc5tuP0MsrtJWrji6x8n4_Psc_xQehZAJMI5hhxQxkHYKDkhRtlAXNzzgWFJSanXAUnJ-95-5C-7bJurfZjwWtpNs0a-eUv40r-B1V4B7iqKNl_QLbqFF7Ab8AXnoAwPP8K4w_9YuocqWwo3519-VX5a5iEr7naxvgoZr2-0xyLrK8T8OzNk8EqZPQWaRkXaX043xlKqHP31vJNzotKrG1VeXLNJvagp9LQE9Ez2aKcDljjX5xmo6LWuZuIy_FopqW_-DzKnOPFQh1bplsmo1MxGIie067Kk_7k9KwMQmsO1F5NY2nfQnvAmcjNho18-7PviRLJHtNbnkZKSyumQ5czk-fLynFzeUzJ12hBKBPPZKErF3jimex7VxYPT59lBSDCzCWgKxdxr1a5hjZ9sE1UvpBXbw6qoysSab_ZatgLCa1MuyUNaFNN5m_WGdZGWd68EBOAsTC5VdYbP1oJ6txGt0rrBTcNFe-gmhzeRdeT0j_jHpKKkdgwEmtGYstI3B9izUhsGPkSr_BxF1te7WLgIp5zEa9wcQsd7u91Wm23TOTh5pQFU7cgmZ9LTjmHFaAofL8gPZGzgGWx8AoqojCUWegLFtIi4BS0VBaJjFDJCk4ZCYP7aGM4GsqHCMd5xmKPQkOwBHjYy0CFFSyPIiHhH_fq6Ln9uGle3nKvkq2cp9rbIuKpAaGOnlb1Lsy9LldqvNDYVMVifKa8IEOWtrsn6adu6-T1UTtOD-poS4NXVaQAO_f9OtoGMNf2vrOE8bwa89VWLIEBWtBTkPjqGE8MJUzolMRgdBEer68RwocksJbX0QPDlnnvFLoPw2D7d2N7hG7MJ-xjtDEdz-QTUL2n2Y6m-k_e5NOS
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Rift+Valley+Fever+Epidemic+in+Saudi+Arabia%3A+Epidemiological%2C+Clinical%2C+and+Laboratory+Characteristics&rft.jtitle=Clinical+infectious+diseases&rft.au=Madani%2C+Tariq+A.&rft.au=Al-Mazrou%2C+Yagob+Y.&rft.au=Al-Jeffri%2C+Mohammad+H.&rft.au=Mishkhas%2C+Amin+A.&rft.date=2003-10-15&rft.pub=The+University+of+Chicago+Press&rft.issn=1058-4838&rft.eissn=1537-6591&rft.volume=37&rft.issue=8&rft.spage=1084&rft.epage=1092&rft_id=info:doi/10.1086%2F378747&rft.externalDocID=10.1086%2F378747
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1058-4838&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1058-4838&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1058-4838&client=summon